Effects of Monacolin K in Nondiabetic Patients with NAFLD: A Pilot Study
暂无分享,去创建一个
C. Catena | L. Sechi | G. Soardo | A. Da Porto | D. Donnini | G. Brosolo | Martina Antonello | Fabio Vanin | Arianna Romanin | Paolo Toritto | Eleonora Varisco
[1] C. Catena,et al. Association of non-alcoholic fatty liver disease with left ventricular changes in treatment-naive patients with uncomplicated hypertension , 2022, Frontiers in Cardiovascular Medicine.
[2] Yanzhang Li,et al. Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease , 2022, International journal of molecular sciences.
[3] Bhornprom Yoysungnoen,et al. Red Rice Bran Extract Attenuates Adipogenesis and Inflammation on White Adipose Tissues in High-Fat Diet-Induced Obese Mice , 2022, Foods.
[4] H. El‐Serag,et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight , 2022, Nature Reviews Gastroenterology & Hepatology.
[5] C. Catena,et al. Differences in Regulation of Cortisol Secretion Contribute to Left Ventricular Abnormalities in Patients With Essential Hypertension , 2022, Hypertension.
[6] C. Catena,et al. Vitamin D Deficiency Is Associated with Glycometabolic Changes in Nondiabetic Patients with Arterial Hypertension , 2022, Nutrients.
[7] C. Catena,et al. Prognostic Role of Malnutrition Diagnosed by Bioelectrical Impedance Vector Analysis in Older Adults Hospitalized with COVID-19 Pneumonia: A Prospective Study , 2021, Nutrients.
[8] P. Fariselli,et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. , 2021, Journal of hepatology.
[9] Pau Vancells Lujan,et al. Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development , 2021, Nutrients.
[10] V. Wong,et al. Non-alcoholic fatty liver disease , 2021, The Lancet.
[11] Sangam Rajak,et al. Current treatment paradigms and emerging therapies for NAFLD/NASH. , 2021, Frontiers in bioscience.
[12] Roberto Rodriguez-Echevarria,et al. Nutritional Approaches for the Management of Nonalcoholic Fatty Liver Disease: An Evidence-Based Review , 2020, Nutrients.
[13] C. Valério,et al. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes , 2020, Diabetology & Metabolic Syndrome.
[14] Zhiting Chen,et al. An overview of the bioactivity of monacolin K / lovastatin. , 2019, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[15] M. Maciejczyk,et al. Oxidative stress biomarkers in the serum and plasma of patients with non-alcoholic fatty liver disease (NAFLD). Can plasma AGE be a marker of NAFLD? Oxidative stress biomarkers in NAFLD patients , 2019, Free radical research.
[16] M. Banach,et al. Red Yeast Rice for Hypercholesterolemia. , 2019, Methodist DeBakey cardiovascular journal.
[17] M. Moreno-Aliaga,et al. Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation , 2019, Nutrients.
[18] M. Friedrich-Rust,et al. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.
[19] T. Asselah,et al. Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases. , 2018, Gastroenterology.
[20] S. Bellentani,et al. Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence , 2018, Nutrients.
[21] E. Manzato,et al. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper , 2018, Pharmacological research.
[22] L. Sechi,et al. Long-Term Renal and Cardiac Outcomes after Stenting in Patients with Resistant Hypertension and Atherosclerotic Renal Artery Stenosis , 2017, Kidney and Blood Pressure Research.
[23] M. Pergolini,et al. Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study. , 2017, Atherosclerosis. Supplements.
[24] A. Facciorusso,et al. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. , 2017, Free radical biology & medicine.
[25] Lian-hui Chen,et al. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials. , 2016, Clinical nutrition.
[26] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[27] I. Hatemi,et al. Role of oxidative stress and insulin resistance in disease severity of non-alcoholic fatty liver disease. , 2016, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.
[28] H. Tilg,et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.
[29] D. Häussinger,et al. Evaluation of Acoustic Radiation Force Impulse Imaging (ARFI) for the Determination of Liver Stiffness Using Transient Elastography as a Reference in Children , 2015, Ultrasound International Open.
[30] F. Violi,et al. Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. , 2015, World journal of hepatology.
[31] V. Gerdes,et al. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. , 2015, Atherosclerosis.
[32] H. Yki-Järvinen. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.
[33] F. Nascimbeni,et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease , 2014, Alimentary pharmacology & therapeutics.
[34] K. Tsuneyama,et al. Study of the Effects of Monacolin K and Other Constituents of Red Yeast Rice on Obesity, Insulin-Resistance, Hyperlipidemia, and Nonalcoholic Steatohepatitis Using a Mouse Model of Metabolic Syndrome , 2012, Evidence-based complementary and alternative medicine : eCAM.
[35] L. Sechi,et al. Oxidative stress is activated by free fatty acids in cultured human hepatocytes. , 2011, Metabolic syndrome and related disorders.
[36] A. Baranova,et al. Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.
[37] B. Neuschwander‐Tetri,et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.
[38] K. Oniki,et al. Association between combinations of glutathione‐S‐transferase M1, T1 and P1 genotypes and non‐alcoholic fatty liver disease , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[39] R. Boldrini,et al. Protein glutathionylation increases in the liver of patients with non‐alcoholic fatty liver disease , 2008, Journal of gastroenterology and hepatology.
[40] M. Holmqvist,et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. , 2007, Journal of hepatology.
[41] C. Catena,et al. Alcohol-induced endothelial changes are associated with oxidative stress and are rapidly reversed after withdrawal. , 2005, Alcoholism, clinical and experimental research.
[42] K. Mak,et al. Model of nonalcoholic steatohepatitis. , 2004, The American journal of clinical nutrition.
[43] G. Svegliati-Baroni,et al. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH , 2019, Transplantation.